3D Medicines
3D Medicines is a commercial-stage oncology company serving cancer patients with envafolimab, its first commercialized subcutaneous PD-L1 antibody.
- Public company
- Shanghai, SH, CNChina
3D Medicines is a commercial-stage oncology company serving cancer patients with envafolimab, its first commercialized subcutaneous PD-L1 antibody.
en.3d-medicines.comCrawled Nov 11, 2026
3D Medicines Inc. (3D Med), a clinical stage biopharmaceutical company focusing on the development and commercialization of next-generation immuno-oncology drugs, has built a comprehensive pipeline to
3D Medicines develops and commercializes next-generation immunotherapy drugs for cancer, focusing on subcutaneous PD-L1 antibody envafolimab as its core product.
3D Medicines receives acceptance of its new drug application (NDA) for **envafolimab**, a potential first-line treatment for **biliary tract cancer**, from China’s National Medical Products Administration (NMPA). The submission marks a key regulatory milestone for the biotech company’s oncology pipeline. Envafolimab targets immune checkpoint pathways to address an aggressive cancer type with limited treatment options.
Jan 2026MarketScreenerNews article
Glenmark Pharmaceuticals begins a Phase 3 clinical trial for its drug **envafolimab** to treat **resectable Stage III non-small cell lung cancer (NSCLC)** across multiple countries. The trial follows approval from India’s Drug Controller General (DCGI) to start patient enrollment. Envafolimab targets immune checkpoint pathways to potentially improve outcomes for NSCLC patients eligible for surgical resection.
Sep 2025prnewswire.co.ukNews article
Glenmark Pharmaceuticals Ltd. secures a global license for **KN035 (Envafolimab)**, a therapeutic antibody, from **Jiangsu Alphamab Biopharmaceuticals** and **3D Medicines Inc.** The agreement covers territories including **India, Asia Pacific (excluding Singapore, Thailand, Malaysia), the Middle East, Africa, Russia, CIS, and Latin America**. The deal expands Glenmark’s access to the drug for potential development and commercialization in these regions.
Jan 2024PR NewswireNews article
Glenmark Specialty S.A. secures a license for **KN035 (Envafolimab)**, a biologic therapy developed by **Jiangsu Alphamab Biopharmaceuticals** and **3D Medicines**. The agreement grants Glenmark rights to commercialize the drug in **India, Asia-Pacific, the Middle East, Africa, Russia, CIS, and Latin America**. The deal expands Glenmark’s oncology portfolio with a potential new treatment option.
Jan 2024Express PharmaNews article